綠葉製藥(02186.HK)完成配發2.92億股 籌資12.51億港元
格隆匯2月8日丨綠葉製藥(02186.HK)公佈,認購協議全部條件已獲達成,故認購協議項下認購事項已於2021年2月8日落實完成。因此,根據認購協議的條款及條件,2.92億股認購股份已配發及發行予Hillhouse NEV,認購價為每股4.28港元。公司所收取所得款項淨額合共約為12.51億港元。公司擬將有關所得款項淨額用作集團的一般營運資金。
公司獲LuYe Investment吿知,根據買賣協議,於2021年2月2日,其已完成向Hillhouse NEV出售2.6億股股份。
此外,孫欣先生已獲委任為公司的非執行董事,自2021年2月8日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.